Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/61467
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Treatment of ocular surface squamous neoplasia with Mitomycin C
Author: Gupta, A.
Muecke, J.
Citation: British Journal of Ophthalmology, 2010; 94(5):555-558
Publisher: British Med Journal Publ Group
Issue Date: 2010
ISSN: 0007-1161
1468-2079
Statement of
Responsibility: 
A. Gupta and J. Muecke
Abstract: Aim: To report the outcome of treatment of non-invasive ocular surface squamous neoplasia (or conjunctivalcorneal intra-epithelial neoplasia (CCIN)) where topical mitomycin C (MMC) has been used in the treatment regimen. Design: Prospective, non-comparative interventional case series. Participants: 91 primary or recurrent CCIN lesions from 90 patients treated in a single ocular oncology centre over a 10.5-year period. Intervention 73 cases of localised, non-invasive CCIN and eight cases of recurrent CCIN received a treatment regimen of surgical excision6cryotherapy, followed by two to three 1-week cycles of adjuvant topical MMC (0.04% four times a day). 10 cases of diffuse CCIN received two to three 1-week cycles of topical MMC (0.04% four times a day) as sole primary treatment. Main outcome measure: Successful treatment was defined as no clinical recurrence of CCIN. Results: Mean follow-up of 56.8 months (range 5.8 to 119.8) and median 57.3 months, revealed no recurrences (0%) in the localised primary group, and one persistent case and two recurrences (30%) in the diffuse primary group. There was one recurrence (12.5%) in the recurrent group, but this was in the only eye with a diffuse type of recurrence. Conclusions: MMC treatment following surgical excision appears to decrease the recurrence rate of localised CCIN and should be considered as adjuvant therapy in primary treatment. MMC should also be considered as adjuvant therapy in the treatment of localised recurrent disease. MMC may be used as sole therapy in more diffuse disease, but close ongoing follow-up is recommended in view of the significant risk of persistent or recurrent disease.
Keywords: Humans; Carcinoma in Situ; Eye Neoplasms; Conjunctival Neoplasms; Neoplasm Recurrence, Local; Corneal Diseases; Mitomycin; Antibiotics, Antineoplastic; Treatment Outcome; Chemotherapy, Adjuvant; Follow-Up Studies; Prospective Studies; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male
Rights: Copyright © The Authors
RMID: 0020097386
DOI: 10.1136/bjo.2009.168294
Appears in Collections:Opthalmology & Visual Sciences publications

Files in This Item:
File Description SizeFormat 
hdl_61467.pdfPublished version85.91 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.